A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer
Overview
Authors
Affiliations
In light of the frequent development of therapeutic resistance in cancer treatment, there is a strong need for personalized model systems representing patient tumor heterogeneity, while enabling parallel drug testing and identification of appropriate treatment responses in individual patients. Using ovarian cancer as a prime example of a heterogeneous tumor disease, we developed a 3D preclinical tumor model comprised of patient-derived microtumors (PDM) and autologous tumor-infiltrating lymphocytes (TILs) to identify individual treatment vulnerabilities and validate chemo-, immuno- and targeted therapy efficacies. Enzymatic digestion of primary ovarian cancer tissue and cultivation in defined serum-free media allowed rapid and efficient recovery of PDM, while preserving histopathological features of corresponding patient tumor tissue. Reverse-phase protein array (RPPA)-analyses of >110 total and phospho-proteins enabled the identification of patient-specific sensitivities to standard, platinum-based therapy and thereby the prediction of potential treatment-responders. Co-cultures of PDM and autologous TILs for individual efficacy testing of immune checkpoint inhibitor treatment demonstrated patient-specific enhancement of cytotoxic TIL activity by this therapeutic approach. Combining protein pathway analysis and drug efficacy testing of PDM enables drug mode-of-action analyses and therapeutic sensitivity prediction within a clinically relevant time frame after surgery. Follow-up studies in larger cohorts are currently under way to further evaluate the applicability of this platform to support clinical decision making.
Functionally-instructed modifiers of response to ATR inhibition in experimental glioma.
Walter B, Hirsch S, Kuhlburger L, Stahl A, Schnabel L, Wisser S J Exp Clin Cancer Res. 2024; 43(1):77.
PMID: 38475864 PMC: 10935927. DOI: 10.1186/s13046-024-02995-z.
Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.
Khorsandi D, Yang J, Foster S, Khosravi S, Kouchehbaghi N, Zarei F Adv Healthc Mater. 2024; 13(21):e2302331.
PMID: 38359321 PMC: 11324859. DOI: 10.1002/adhm.202302331.
Emerging roles of 3D-culture systems in tackling tumor drug resistance.
Nikdouz A, Orso F Cancer Drug Resist. 2024; 6(4):788-804.
PMID: 38263982 PMC: 10804388. DOI: 10.20517/cdr.2023.93.
Can Nitric Oxide-Based Therapy Be Improved for the Treatment of Cancers? A Perspective.
Sinha B Int J Mol Sci. 2023; 24(17).
PMID: 37686417 PMC: 10487592. DOI: 10.3390/ijms241713611.
Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C J Exp Clin Cancer Res. 2023; 42(1):210.
PMID: 37596623 PMC: 10436441. DOI: 10.1186/s13046-023-02782-2.